Home > Legislation > 116th Congress > H.R.8662

H.R.8662 - Accelerating Access to Critical Therapies for ALS Act116th Congress (2019-2020)

Bill

Hide Overview
Sponsor: Rep. Fortenberry, Jeff [R-NE-1] (Introduced 10/23/2020)
Committees: House - Energy and Commerce
Latest Action: House - 10/23/2020 Referred to the House Committee on Energy and Commerce.  (All Actions)

Tracker:

This bill has the status Introduced

Here are the steps for Status of Legislation:

  1. Introduced

More on This Bill

  • Constitutional Authority Statement
  • CBO Cost Estimates [0]

Subject — Policy Area:

Summary: H.R.8662 — 116th Congress (2019-2020)All Information (Except Text)

There is one summary for H.R.8662. Bill summaries are authored by CRS.

Shown Here:
Introduced in House (10/23/2020)

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.